Biology subjects

Baban, B.

Publications and source records attributed to Baban, B..

12 recordsLinked to original sources

bioRxiv2026

A Shifting Immune Landscape: ILC Redistribution and Neutrophil Polarization in Vascular Cognitive Impairment and Dementia (VCID)

Vascular cognitive impairment and dementia (VCID) is increasingly recognized as a major contributor to cognitive decline; however, the mechanisms through which vascular dysfunction drives innate immune dysregulation remain poorly understood. In this study, we explore the impact of VCID on the cerebral innate immune landscape, focusing on innate lymphoid cells (ILCs) and neutrophils, two key players in neuroinflammation and brain immune homeostasis. Using a murine model of VCID induced by bilateral common carotid artery stenosis (BCAS) with modifications in C57BL/6 mice, we investigated innate immune cell distribution, polarization, and functional profiles using flow cytometry and immunofluorescence staining. Our findings reveal a compartment-specific shift in ILC populations, with a reduction of ILC2s in the meninges and concurrent expansion in the choroid plexus, accompanied by altered cytokine production. Furthermore, VCID drove a marked shift in neutrophil polarization toward a pro-inflammatory N1-like phenotype in both the meninges and choroid plexus. Critically, immunofluorescence staining of hippocampal brain sections confirmed that activated N1-like neutrophils, characterized by elevated IL-1{beta} and MPO and reduced IL-10, infiltrate the hippocampal parenchyma in VCID, suggesting a spatially progressive innate immune response spanning from CNS border compartments to brain tissue. These results identify a novel innate immune signature in VCID, compartment-specific ILC redistribution, pro-inflammatory neutrophil polarization at CNS borders, and parenchymal neutrophil infiltration in the hippocampus, which may collectively amplify neuroinflammation and accelerate cognitive decline, identifying potential therapeutic targets for vascular-related dementia.

immunology↗

bioRxiv2026

Targeting a Granulocytic/Microbiome Axis Reverses Glioblastoma Progression via Intranasal Cannabidiol

Mucosal cannabidiol formulations are known regulators of the glioblastoma microenvironment, yet the underlying origin point triggering this stroma-remodeling efficacy remains entirely unknown. Here, by mapping innate cell trafficking pathways, we define a novel baseline neuro-immune-microbiome axis in orthotopic glioblastoma, characterized by diverse microbial communities, likely seeded via blood-brain barrier disruption, paired with dense infiltration of host mast cells and mature, crystalloid-containing eosinophils. Localized intranasal administration of a synthetic cannabidiol formulation achieved striking therapeutic efficacy, driving dramatic tumor regression. Mechanistically, high-throughput 16S rRNA sequencing and quantitative flow cytometry revealed this progression was subverted by taming the tumor ecosystem; cannabidiol restricted chaotic microbial diversity, selectively filtering the landscape toward Delftia and depleting Archaea, while simultaneously suppressing hyper-inflammatory host mast cell and eosinophil populations. This study builds upon established innate trafficking frameworks to present the first therapeutically targetable stromal-microbial axis in neuro-oncology.

cancer biology↗

bioRxiv2025

Adoptive Transfer of ILC2s into the Brain Reveals Tumor Homing in Glioblastoma: A Proof-of-Concept for Cellular Therapy

Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor immune cell infiltration. Cellular immunotherapies have transformed cancer treatment but remain largely ineffective against GBM due to the restrictive blood-brain barrier (BBB) and its profoundly immunosuppressive microenvironment. Innate lymphoid cells type 2 (ILC2s) have recently emerged as potential candidates for cellular immunotherapy because of their regenerative and immunomodulatory functions. Here, we provide the first in vivo evidence that systemically administered ILC2s can cross the BBB and home to glioblastoma. Bone marrow-derived ILC2s from C57BL/6 mice were labeled with CFSE and intravenously transferred into hosts bearing orthotopic, luciferase-expressing GL261 tumors. Fluorescence imaging and flow cytometry analyses indicated that transferred ILC2s successfully entered the brain, localized within tumor tissue, and were also detected in meninges and peripheral organs. Although no measurable reduction in tumor growth was observed, these findings support a proof-of-concept for adoptive ILC2 transfer as a feasible approach for targeting CNS tumors and exploring their immunomodulatory potential in GBM.

immunology↗

bioRxiv2025

Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation

PurposeGlioblastoma (GBM) is one of the most aggressive brain tumors, with limited treatment options and poor outcomes due to frequent relapse after surgery. This study aims to investigate whether pretreatment with inhaled cannabidiol (CBD) can inhibit GBM growth in a preclinical murine model. Specifically, we hypothesize that CBD pretreatment may reduce tumor progression and modulate the tumor microenvironment. MethodsC57BL/6 mice were pretreated with inhaled CBD for either 3 or 14 days, or a placebo, followed by intracranial implantation of glioblastoma cells. Tumor growth, immune checkpoint expression (IDO, PD-L1), and key biomarkers (MGMT, Ki67) were assessed to determine the impact of CBD pretreatment on tumor progression and the immune microenvironment. ResultsThe 14-day CBD pretreatment significantly reduced tumor growth compared to both the placebo and 3-day CBD groups. Additionally, this group showed lower expression of immune checkpoints (IDO, PD-L1) and reduced levels of MGMT and Ki67, suggesting enhanced tumor suppression. These results indicate that prolonged CBD pretreatment modulates the tumor microenvironment and may improve tumor control and reduce relapse risk. ConclusionThis study demonstrates that inhaled CBD pretreatment significantly inhibits GBM growth in a preclinical model. CBDs ability to reduce immune checkpoint expression and key biomarkers associated with tumor progression suggests that it could be an effective strategy for enhancing the efficacy of GBM therapies and potentially improving post-surgical outcomes. Further research is required to investigate its clinical potential and mechanisms of action.

cancer biology↗

bioRxiv2025

Protective role of Cannabidiol against nicotine pouch-induced seizure aggravation and alterations in brain glymphatic biomarkers.

Nicotine pouches are increasingly popular as a smokeless alternative to tobacco, yet their long-term neurological effects remain poorly understood. In this preclinical study, we investigated the time-dependent impact of oral nicotine pouch exposure on seizure susceptibility, glymphatic function, and neuroinflammation in mice, and evaluated the therapeutic potential of inhaled cannabidiol (CBD). Using the Racine scale, we found that acute nicotine exposure transiently reduced seizure severity, while chronic exposure significantly exacerbated seizures and impaired glymphatic integrity, as evidenced by downregulation of aquaporin-4 (AQP4). Chronic nicotine also elevated circulating levels of HMGB1 and IL-6, indicating sustained systemic inflammation. Notably, inhaled CBD reversed these pathological changes, reducing seizure severity, restoring AQP4 expression, and normalizing inflammatory markers. Molecular analyses further revealed upregulation of BDNF and c-FOS with chronic nicotine exposure, which was also mitigated by CBD. In conclusion, these findings suggest that while nicotine pouches may confer short-term neurophysiological modulation, chronic use poses significant risks for seizure vulnerability and glymphatic dysfunction. Inhaled CBD demonstrates strong neuroprotective potential and may serve as a promising therapeutic approach for individuals exposed to prolonged nicotine use. HighlightsO_LIChronic exposure to oral nicotine pouches exacerbates seizure severity in a preclinical model. C_LIO_LINicotine-induced seizures are associated with elevated neuroinflammation and impaired glymphatic function. C_LIO_LIInhaled cannabidiol (CBD) reverses nicotine-induced increases in HMGB1, IL-6, and seizure activity. C_LIO_LICBD restores Aquaporin-4 expression and reestablishes glymphatic integrity disrupted by nicotine. C_LIO_LISystems biology analysis reveals an IL-6-centered protein network targeted by CBD, offering mechanistic insight into its neuroprotective effects. C_LI

neuroscience↗

bioRxiv2025

Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control

Alzheimers disease has traditionally been associated with amyloid-{beta} plaques, but growing evidence underscores the role of neuroinflammation in disease progression. The autoimmune hypothesis of Alzheimers disease suggests chronic inflammation and immune dysfunction contribute to neuronal damage, making modulation of immune responses a promising therapeutic strategy for the disease. Cannabidiol, a phytocannabinoid with anti-inflammatory properties, may offer therapeutic potential. This study explores how cannabidiol influences the Indoleamine 2,3-dioxygenase (IDO) and cyclic GMP-AMP synthase (cGAS) pathway, a key regulator of neuroinflammation in Alzheimers disease. Using the 5XFAD transgenic mouse model of Alzheimers disease, we administered cannabidiol via inhalation. We assessed immune markers, including Indoleamine 2,3-dioxygenase and cyclic GMP-AMP synthase, through flow cytometry, immunofluorescence staining, and gene expression analysis. Cytokine levels and neuroinflammatory responses were evaluated, and protein-protein interactions within the Indoleamine 2,3-dioxygenase/cyclic GMP-AMP synthase pathway were analyzed using the STRING database. Cannabidiol treatment significantly reduced Indoleamine 2,3-dioxygenase and cyclic GMP-AMP synthase expression, correlating with lower levels of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha, Interleukin-1 beta, and Interferon-gamma. Bioinformatics analysis identified potential interactions between cannabidiol and immune targets such as Protein Kinase B (AKT1), Transient Receptor Potential Vanilloid 1, and G-protein coupled receptor 55, suggesting a multi-targeted therapeutic effect. These findings support cannabidiol as a potential monotherapy or adjunctive treatment for Alzheimers disease, targeting neuroinflammatory pathways, particularly the Indoleamine 2,3-dioxygenase/cyclic GMP-AMP synthase axis. Further studies are needed to explore its full therapeutic potential.

immunology↗

bioRxiv2024

Optimization of Seizure Prevention by Cannabidiol (CBD)

ObjectiveCannabidiol (CBD) is one of the most prominent non-psychotropic cannabinoids with known therapeutic potentials. Based on its anti-seizure efficacy, the first cannabis derived, pharmaceutical grade CBD-based medication was approved in the USA in 2018 for the treatment of seizures in patients 2 years and older. Despite the effectiveness in reducing seizures, there remain several major questions on the optimization of CBD therapy for epilepsy such as the optimal dosage, composition, and route of delivery, which are the main objective of this current study. MethodsWe evaluated the antiseizure effects of CBD through different compositions, routes of delivery, and dosages in a pre-clinical model. We used a kainic acid-induced epilepsy model in C57BL/6 mice, treated them with placebo and/or CBD through inhalation, oral and injection routes. We used CBD broad spectrum (inhaled and injection) versus CBD isolate formulations. We employed the Racine scaling system to evaluate the severity of the seizures, flow cytometry for measuring Immune biomarkers and neurotrophic factors, and histologic analysis to examine and compare the groups. ResultsOur findings showed that all forms of CBD reduced seizures severity. Among the combination of CBD tested. CBD broad spectrum via inhalation was the most effective in the treatment of epileptic seizures (p<0.05) compared to other forms of CBD treatments. ConclusionOur data suggest that route and CBD formulations affect its efficacy in the prevention of epileptic seizures. Inhaled broad spectrum CBD showed a potential superior effect compared to other delivery routes and CBD formulations in the prevention of epileptic seizures, warrants further research.

neuroscience↗

bioRxiv2024

The role of dietary patterns in the polarization of angiogenic uterine Natural Killer cells during murine pregnancy

Uterine Natural Killer (uNK) cells, predominant leukocytes in mouse and human pregnant uteruses, play crucial roles in angiogenesis and pregnancy protection. In mice, DBA lectin-reactive uNK cells expressing Gal-N-Ac sugar exhibit angiogenic functions essential for pregnancy maintenance. This study compares the impact of different nutritional imbalances on mouse pregnancy and the activation of angiogenic DBA+ uNK cells to safeguard against pregnancy complications. High Fat (HF), High Carbohydrate (HC), High Protein (HP), and Food Restriction (FR) diets were administered from gestation day (GD) 1 to GD10 or until parturition. HF and HC diets led to reduced expression of DBA-identified N-acetyl-D-galactosamine, akin to LPS-induced inflammation, and decreased uNK perforin levels. Additionally, HF and HC diets resulted in elevated endometrial cleaved caspase-3 and decreased smooth muscle alpha-actin, causing blood vessel wall thinning without jeopardizing pregnancy term. FR impaired uNK differentiation, manifesting as an "all-or-none" phenomenon with 50% pregnancy failure. Our findings highlight the intricate relationship between nutritional imbalances and mouse pregnancy outcomes. Notably, high-fat diets elicited pronounced responses from DBA+ uNK cells, while high-protein diets had relatively weaker effects. This study underscores the importance of comprehending uNK cell dynamics in maintaining pregnancy homeostasis under diverse dietary conditions, paving the way for elucidating molecular mechanisms governing these interactions. By shedding light on these complex relationships, this research offers valuable insights for improving maternal and fetal health in the context of nutritional interventions during pregnancy.

immunology↗

bioRxiv2024

Cannabidiol reverses fentanyl-induced addiction and modulates neuroinflammation

IntroductionFentanyl and non-pharmaceutical fentanyl use have been the leading causes of opioid-induced death worldwide. Being 50 times stronger than heroin and 100 times stronger than morphine, fentanyl is a potent opioid with overdoses causing over 250,000 deaths since 2018 in the US alone. The treatment of fentanyl addiction is a complex process and a clinical challenge. There is a dire need to find other innovative and alternative modalities in the fight against fentanyl crisis. Increasing evidence suggests a correlation between neuroinflammation and symptoms of drug abuse, opening up the possibility of immunoregulatory agents as therapy for fentanyl addiction as well as a other opioid-induced addiction. Cannabidiol (CBD) is a non-opioid, relatively safe, non-psychoactive phyto-cannabinoid produced by cannabis plants. Importantly, recent reports have documented benefits of CBD in the treatment and management of complications related to opioid withdrawal. We investigated if inhaled CBD could reverse the fentanyl addiction and whether the CBD treatment could ameliorate the addiction symptoms by regulating neuroinflammatory signals and re-establishing the homeostasis in CNS. MethodWe used a fentanyl-induced conditioned place preference (CPP) model in mouse to test whether inhaled CBD could reverse the fentanyl addiction and ameliorate the adversarial symptoms. By employing a combination of flow cytometry as well as behavioral tests, we further assessed the impact of fentanyl addiction on cells and neuroinflammatory signals in CNS and we measured the effects of CBD in the treatment of addiction symptoms and inflammatory signals. ResultsOur findings suggest that CBD inhalation could be used effectively in the treatment of fentanyl addiction. CBD mitigated the excessive fentanyl-induced neuroinflammatory responses and decreased cellular stress and senescence. Conclusioninhaled CBD could alleviate the fentanyl addiction and regulate neuroinflammatory responses. This novel approach is non-invasive, accessible, effective, and warrants further, translational and research.

animal behavior and cognition↗

bioRxiv2024

The synergy between cannabidiol and probiotics curtails the glycemic indicators, enhances insulin production, and alleviates the symptoms of type 2 diabetes.

Diabetes continues to challenge healthcare system as one of the most growing epidemics with staggering economic burden. It is estimated that 783 million by 2045 will live with diabetes worldwide, 90% of those cases are type 2 diabetes (T2D). T2D is a multifaceted disease, its treatment requires a holistic approach, beyond single target medications with high efficacy. There is a dire need to explore and invent new and effective therapeutic modalities for T2D. In this study we tested whether a combined formulation of cannabidiol (CBD) and probiotics could control glycemic indices and alleviate symptoms of T2D. We used a mouse model of T2D, replaced their drinking water with a combination of CBD and probiotics formulated as a commercially available beverage. Our findings demonstrated that combination of CBD and probiotics not only reduced the glycemic indices (HbA1c & FBG), but also altered the microbiome profile, promoted beneficial bacteria. Further, the CBD/probiotic combination reduced peripheral inflammatory cytokines and enhanced insulin production in pancreatic islets. In conclusion, our results suggest that consumption of combined CBD and probiotics could be used as a natural, practical, affordable, and safe alternative and complementary therapeutic modality to treat T2D.

molecular biology↗

bioRxiv2022

Apolipoprotein E4 has extensive conformational heterogeneity in lipid free and bound forms

The {varepsilon}4-allele variant of Apolipoprotein E (ApoE4) is the strongest genetic risk factor for Alzheimers disease, though it only differs from its neutral counterpart ApoE3 by a single amino acid substitution. While ApoE4 influences the formation of plaques and neurofibrillary tangles, the structural determinants of pathogenicity remain undetermined due to limited structural information. We apply a combination of single-molecule spectroscopy and molecular dynamics simulations to construct an atomically-detailed model of monomeric ApoE4 and probe the effect of lipid association. Our data reveal that ApoE4 is far more disordered than previously thought and retains significant conformational heterogeneity after binding lipids. In particular, the behavior of the hinge region and C-terminal domain of ApoE4 differs substantially from that proposed in previous models and provides a crucial foundation for understanding how ApoE4 differs from non-pathogenic and protective variants of the protein.

biophysics↗

bioRxiv2020

Functional insights from biophysical study of TREM2 interactions with ApoE and Aβ1-42

INTRODUCTIONTREM2 is an innate immune receptor expressed on myeloid cells including microglia in the brain. How TREM2 engages different ligands remains poorly understood. METHODSWe used comprehensive BLI analysis to investigate the TREM2 interactions with ApoE and monomeric amyloid beta (mA{beta}42). RESULTSTREM2 binding did not depend on ApoE lipidation, and there were only slight differences in affinity observed between ApoE isoforms (E4 > E3 > E2). Surprisingly, disease-linked TREM2 variants within a "basic patch" minimally impact ApoE binding. Instead, TREM2 has a unique hydrophobic surface that can bind to ApoE. This direct engagement requires the hinge region of ApoE. TREM2 directly binds mA{beta}42 and can potently inhibit A{beta}42 polymerization, suggesting a potential mechanism for soluble TREM2 (sTREM2) in preventing AD pathogenesis. DISCUSSIONThese findings demonstrate that TREM2 has at least two separate surfaces to engage ligands and uncovers a potential function for sTREM2 in directly inhibiting A{beta} polymerization.

biophysics↗